1. Home
  2. FNUC vs TCRX Comparison

FNUC vs TCRX Comparison

Compare FNUC & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

FNUC

Frontier Nuclear and Minerals Inc. Common Shares

N/A

Current Price

$2.44

Market Cap

65.5M

ML Signal

N/A

Logo TScan Therapeutics Inc.

TCRX

TScan Therapeutics Inc.

HOLD

Current Price

$1.06

Market Cap

63.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FNUC
TCRX
Founded
2018
2018
Country
Canada
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.5M
63.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
FNUC
TCRX
Price
$2.44
$1.06
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$7.00
AVG Volume (30 Days)
300.4K
964.6K
Earning Date
03-26-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.28
EPS
N/A
N/A
Revenue
N/A
$10,325,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$19.81
P/E Ratio
N/A
N/A
Revenue Growth
N/A
266.65
52 Week Low
$1.89
$0.88
52 Week High
$2.82
$2.57

Technical Indicators

Market Signals
Indicator
FNUC
TCRX
Relative Strength Index (RSI) 60.37 47.94
Support Level $2.26 $0.90
Resistance Level $2.51 $1.24
Average True Range (ATR) 0.23 0.07
MACD 0.01 0.00
Stochastic Oscillator 52.44 49.25

Price Performance

Historical Comparison
FNUC
TCRX

About FNUC Frontier Nuclear and Minerals Inc. Common Shares

Frontier Nuclear and Minerals Inc is developing a U.S.-focused front-end nuclear fuel cycle company through a portfolio of U.S. uranium exploration and development projects in Wyoming, Colorado, and Utah, together with investments in next-generation uranium enrichment and small modular reactors. Frontier Nuclear is actively evaluating value-accretive investment opportunities in other sectors of the domestic U.S. nuclear fuel cycle. The group is developing a portfolio of critical minerals projects in America, Canada, and Namibia, including uranium, tantalum, cesium, and lithium. Its projects are Engo Valley, Pine Ridge, Shatford Lake, Snow Lake Lithium, and Tallahassee.

About TCRX TScan Therapeutics Inc.

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Share on Social Networks: